Vanguard Group Inc. Has $120.89 Million Position in Edgewise Therapeutics, Inc. $EWTX

Vanguard Group Inc. raised its position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) by 1.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,871,624 shares of the company’s stock after purchasing an additional 67,683 shares during the period. Vanguard Group Inc.’s holdings in Edgewise Therapeutics were worth $120,889,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of EWTX. Universal Beteiligungs und Servicegesellschaft mbH grew its holdings in shares of Edgewise Therapeutics by 104.8% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 271,385 shares of the company’s stock valued at $6,734,000 after buying an additional 138,882 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Edgewise Therapeutics by 64.1% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,265 shares of the company’s stock worth $280,000 after buying an additional 4,402 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in Edgewise Therapeutics by 26.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,145 shares of the company’s stock valued at $128,000 after acquiring an additional 1,072 shares in the last quarter. Aberdeen Group plc lifted its holdings in shares of Edgewise Therapeutics by 32.6% in the fourth quarter. Aberdeen Group plc now owns 821,940 shares of the company’s stock valued at $20,396,000 after purchasing an additional 202,062 shares in the last quarter. Finally, SG Americas Securities LLC boosted its position in shares of Edgewise Therapeutics by 797.9% during the fourth quarter. SG Americas Securities LLC now owns 88,723 shares of the company’s stock worth $2,202,000 after buying an additional 78,842 shares during the period.

Edgewise Therapeutics Stock Performance

Shares of NASDAQ EWTX opened at $34.01 on Wednesday. The stock’s fifty day moving average is $31.79 and its 200 day moving average is $27.23. The stock has a market capitalization of $3.66 billion, a P/E ratio of -20.49 and a beta of 0.25. Edgewise Therapeutics, Inc. has a 52 week low of $12.15 and a 52 week high of $39.96.

Edgewise Therapeutics (NASDAQ:EWTX) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.04. Equities research analysts forecast that Edgewise Therapeutics, Inc. will post -2.14 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Edgewise Therapeutics in a report on Monday, April 20th. HC Wainwright upgraded Edgewise Therapeutics to a “strong-buy” rating in a research note on Thursday, February 26th. Wall Street Zen lowered shares of Edgewise Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Wedbush reiterated an “outperform” rating and set a $32.00 target price on shares of Edgewise Therapeutics in a research note on Tuesday, March 17th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Edgewise Therapeutics in a research note on Monday, February 9th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $39.67.

Insider Activity at Edgewise Therapeutics

In related news, CMO Joanne M. Donovan sold 50,000 shares of the company’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $38.57, for a total transaction of $1,928,500.00. Following the completion of the sale, the chief marketing officer directly owned 4,367 shares in the company, valued at $168,435.19. This represents a 91.97% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders sold 83,892 shares of company stock worth $3,018,216. 23.20% of the stock is currently owned by insiders.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.